Business Description
Clarity Pharmaceuticals Ltd
ISIN : AU0000165375
Description
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.95 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | 60.09 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.28 | |||||
| 9-Day RSI | 50.7 | |||||
| 14-Day RSI | 46.96 | |||||
| 6-1 Month Momentum % | 55.87 | |||||
| 12-1 Month Momentum % | 453.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.05 | |||||
| Quick Ratio | 19.05 | |||||
| Cash Ratio | 16.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -5.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -47.28 | |||||
| ROA % | -43.83 | |||||
| ROIC % | -523.2 | |||||
| ROC (Joel Greenblatt) % | -1052.93 | |||||
| ROCE % | -62.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 13.67 | |||||
| Price-to-Tangible-Book | 13.64 | |||||
| EV-to-EBIT | -34.03 | |||||
| EV-to-EBITDA | -34.12 | |||||
| EV-to-FCF | -43.8 | |||||
| Price-to-Net-Current-Asset-Value | 13.64 | |||||
| Price-to-Net-Cash | 15.63 | |||||
| Earnings Yield (Greenblatt) % | -2.94 | |||||
| FCF Yield % | -2.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Clarity Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.155 | ||
| Beta | 1.59 | ||
| Volatility % | 88.05 | ||
| 14-Day RSI | 46.96 | ||
| 14-Day ATR (A$) | 0.440557 | ||
| 20-Day SMA (A$) | 6.6085 | ||
| 12-1 Month Momentum % | 453.25 | ||
| 52-Week Range (A$) | 1.355789 - 8.975 | ||
| Shares Outstanding (Mil) | 320.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clarity Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clarity Pharmaceuticals Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Clarity Pharmaceuticals Ltd Frequently Asked Questions
What is Clarity Pharmaceuticals Ltd(ASX:CU6)'s stock price today?
The current price of ASX:CU6 is A$6.41. The 52 week high of ASX:CU6 is A$8.98 and 52 week low is A$1.36.
When is next earnings date of Clarity Pharmaceuticals Ltd(ASX:CU6)?
The next earnings date of Clarity Pharmaceuticals Ltd(ASX:CU6) is .
Does Clarity Pharmaceuticals Ltd(ASX:CU6) pay dividends? If so, how much?
Clarity Pharmaceuticals Ltd(ASX:CU6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers